Lyell Immunopharma, Inc. Operating Expenses
Lyell Immunopharma, Inc. (LYEL) reported Operating Expenses of $47.34 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- Lyell Immunopharma, Inc. operating expenses for the quarter ending 2026-06-30 was $47.34M, a 0.41% increase year-over-year.
- Lyell Immunopharma, Inc. operating expenses for the quarter ending 2026-03-31 was $44.26M, a 22.85% decline year-over-year.
- Lyell Immunopharma, Inc. operating expenses for the quarter ending 2025-12-31 was $127.65M, a 36.54% decline year-over-year.
- Lyell Immunopharma, Inc. operating expenses for the quarter ending 2025-09-30 was $37.27M, a 26.26% decline year-over-year.
- Lyell Immunopharma, Inc. operating expenses for fiscal 2025 was $269.44M, a 24.91% decline from fiscal 2024.
- Lyell Immunopharma, Inc. operating expenses for fiscal 2024 was $358.82M, a 45.19% increase from fiscal 2023.
- Lyell Immunopharma, Inc. operating expenses for fiscal 2023 was $247.14M, a 9.05% decline from fiscal 2022.
- Lyell Immunopharma, Inc. operating expenses for fiscal 2022 was $271.74M, a 20.55% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $47.34M 10-Q · filed 2026-08-06 | $91.60M 10-Q · filed 2026-08-06 | $219.25M derived: sum of 3 quarters · filed 2026-08-06 | $256.52M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $44.26M 10-Q · filed 2026-05-06 | $171.91M derived: sum of 2 quarters · filed 2026-05-06 | $209.18M derived: sum of 3 quarters · filed 2026-05-06 | $256.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $127.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $164.92M derived: sum of 2 quarters · filed 2026-03-12 | $212.07M derived: sum of 3 quarters · filed 2026-08-06 | $269.44M 10-K · filed 2026-03-12 |
| 2025-09-30 | $37.27M 10-Q · filed 2025-11-12 | $84.42M derived: sum of 2 quarters · filed 2026-08-06 | $141.79M 10-Q · filed 2025-11-12 | $342.95M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $47.15M 10-Q · filed 2026-08-06 | $104.52M 10-Q · filed 2026-08-06 | $305.68M derived: sum of 3 quarters · filed 2026-08-06 | $356.22M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $57.37M 10-Q · filed 2026-05-06 | $258.53M derived: sum of 2 quarters · filed 2026-05-06 | $309.07M derived: sum of 3 quarters · filed 2026-05-06 | $360.61M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $201.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $251.70M derived: sum of 2 quarters · filed 2026-03-12 | $303.24M derived: sum of 3 quarters · filed 2026-03-12 | $358.82M 10-K · filed 2026-03-12 |
| 2024-09-30 | $50.54M 10-Q · filed 2025-11-12 | $102.08M derived: sum of 2 quarters · filed 2025-11-12 | $157.66M 10-Q · filed 2025-11-12 | $217.18M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | $51.54M 10-Q · filed 2025-08-12 | $107.12M 10-Q · filed 2025-08-12 | $166.64M derived: sum of 3 quarters · filed 2026-03-12 | $225.70M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | $55.58M 10-Q · filed 2025-05-13 | $115.10M derived: sum of 2 quarters · filed 2026-03-12 | $174.16M derived: sum of 3 quarters · filed 2026-03-12 | $240.09M derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | $59.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $118.58M derived: sum of 2 quarters · filed 2026-03-12 | $184.52M derived: sum of 3 quarters · filed 2026-03-12 | $247.14M 10-K · filed 2026-03-12 |
| 2023-09-30 | $59.06M 10-Q · filed 2024-11-07 | $125.00M derived: sum of 2 quarters · filed 2024-11-07 | $187.62M 10-Q · filed 2024-11-07 | $250.79M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | $65.93M 10-Q · filed 2024-08-07 | $128.55M 10-Q · filed 2024-08-07 | $191.72M derived: sum of 3 quarters · filed 2025-03-11 | $258.16M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-03-31 | $62.62M 10-Q · filed 2024-05-06 | $125.79M derived: sum of 2 quarters · filed 2025-03-11 | $192.23M derived: sum of 3 quarters · filed 2025-03-11 | $265.23M derived: sum of 4 quarters · filed 2025-03-11 |
| 2022-12-31 | $63.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $129.61M derived: sum of 2 quarters · filed 2025-03-11 | $202.61M derived: sum of 3 quarters · filed 2025-03-11 | $271.74M 10-K · filed 2025-03-11 |
| 2022-09-30 | $66.44M 10-Q · filed 2023-11-07 | $139.44M derived: sum of 2 quarters · filed 2023-11-07 | $208.57M 10-Q · filed 2023-11-07 | $258.93M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $73.00M 10-Q · filed 2023-08-08 | $142.13M 10-Q · filed 2023-08-08 | $192.49M derived: sum of 3 quarters · filed 2024-02-28 | $244.41M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $69.13M 10-Q · filed 2023-05-04 | $119.49M derived: sum of 2 quarters · filed 2024-02-28 | $171.41M derived: sum of 3 quarters · filed 2024-02-28 | $236.74M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $50.36M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $102.28M derived: sum of 2 quarters · filed 2024-02-28 | $167.61M derived: sum of 3 quarters · filed 2024-02-28 | $225.43M 10-K · filed 2024-02-28 |
| 2021-09-30 | $51.92M 10-Q · filed 2022-11-08 | $117.25M derived: sum of 2 quarters · filed 2022-11-08 | $175.07M 10-Q · filed 2022-11-08 | $216.90M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $65.33M 10-Q · filed 2022-08-04 | $123.15M 10-Q · filed 2022-08-04 | $164.99M derived: sum of 3 quarters · filed 2023-02-28 | $202.90M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $57.81M 10-Q · filed 2022-05-10 | $99.65M derived: sum of 2 quarters · filed 2023-02-28 | $137.56M derived: sum of 3 quarters · filed 2023-02-28 | $243.25M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $41.84M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $79.75M derived: sum of 2 quarters · filed 2023-02-28 | $185.43M derived: sum of 3 quarters · filed 2023-02-28 | $219.69M 10-K · filed 2023-02-28 |
| 2020-09-30 | $37.91M 10-Q · filed 2021-11-12 | $143.60M derived: sum of 2 quarters · filed 2021-11-12 | $177.86M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $105.68M 10-Q · filed 2021-08-12 | $139.94M 10-Q · filed 2021-08-12 | ||
| 2019-12-31 | $102.75M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |